EnVivo is taking a multi-target, multi-program approach to developing safe and effective CNS treatments - our broad and diverse pipeline enhances our ability to address diseases like Alzheimer's disease, schizophrenia and other neurodegenerative diseases using multiple mechanisms and possible complementary therapies.
19 Apr 2012
EnVivo Pharmaceuticals Names Christopher L. Burnley Chief Business Officer